home / stock / bfriw / bfriw news

BFRIW News and Press, Biofrontera Inc. Warrants From 11/08/22

Stock Information
Company Name: Biofrontera Inc. Warrants
Stock Symbol: BFRIW
Market: NASDAQ
Website: biofrontera-us.com
Menu
BFRIW BFRIW Quote BFRIW Short BFRIW News BFRIW Articles BFRIW Message Board
Get BFRIW Alerts

News, Short Squeeze, Breakout and More Instantly...
BFRIW - Biofrontera Inc. Fully Exercises Recently Acquired Options to Purchase Shares of Biofrontera AG

WOBURN, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today the exercise in full of options to purchase 2,623,365 ordinary shares of Biofronter...
BFRIW - Biofrontera Inc. Enters into Agreements to Purchase Options of Biofrontera AG

Sets company up to realize full commercial potential in fast growing U.S. market Supports mutually beneficial interests between Biofrontera Inc and Biofrontera AG WOBURN, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical co...

BFRIW - Biofrontera Inc. Names Fred Leffler as Chief Financial Officer

WOBURN, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces the appointment of Fred Leffler as Chief Financial Officer, effective immediately. Mr. Leffle...

BFRIW - Biofrontera Inc. to Present at the LD Micro Main Event XV Investor Conference

WOBURN, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that Erica Monaco, Chief Executive Officer, will be presenting and meeting with reg...
BFRIW - Biofrontera Inc. to Sponsor the 2022 Fall Clinical Dermatology Conference

Four Posters Highlight ing Results from Investigator-Initiated and Company-Sponsored Research with Ameluz to be Presented WOBURN, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commerc...

BFRIW - Biofrontera Inc. Adopts Limited Duration Shareholder Rights Plan

WOBURN, Mass., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”) , a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that its Board of Directors has adopted a limite...

BFRIW - BIOFRONTERA INC. TO PARTICIPATE IN RENMARK'S VIRTUAL NON-DEAL ROADSHOW SERIES ON FRIDAY OCTOBER 14, AND TUESDAY OCTOBER 18, 2022

WOBURN, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. ("Biofrontera" or the "Company") (NASDAQ: BFRI), announced today that they will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series to discuss its latest investor prese...
BFRIW - Biofrontera Inc. Announces Preliminary Product Revenues for the Third Quarter of 2022

WOBURN, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced preliminary unaudited product revenues for the three and nine months ended September 30...

BFRIW - Biofrontera Inc. to Present at the Roth Inaugural Healthcare Opportunities Conference

WOBURN, Mass., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that Erica Monaco, Chief Executive Officer, will present at the Roth Inaugural Healthc...

BFRIW - Biofrontera Inc.'s Marketing Campaign and Website for Ameluz Won 2022 PM360 Trailblazer Awards

WOBURN, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that PM360 , a publication for marketing decision makers in the pharmaceutical, bi...
Previous 10 Next 10